This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

"Medical Insights" Project From SAP To Accelerate Personalized Treatment For Cancer Patients

Stocks in this article: SAP

ORLANDO, Fla., Feb. 24, 2014 /PRNewswire/ -- To support patients in receiving the maximum benefit from every research and healthcare dollar spent, SAP AG (NYSE: SAP) is developing innovative solutions aimed at significantly improving health outcomes while cutting costs and improving outcomes at each step of healthcare delivery. Providing the latest example, the company today announced the first early, live deployment of the project "Medical Insights" for clinical data integration, an important advancement in cancer treatment. The announcement was made at HIMSS14, being held February 23-27 in Orlando, Florida.

SAP Logo

"The entire healthcare community recognizes the need to simplify and extract data for the benefit of individual patients," said Bill McDermott, co-CEO and member of the Executive Board of SAP AG. "With the 'Medical Insights' project, we're working on being able to unleash the power of the SAP HANA platform and apply this breakthrough to improving patient care. There is no question that real-time data and analytics will drive more personalized care and better outcomes throughout the healthcare system."

Almost every instance of cancer is unique. There is an immense volume and variety of information processed in providing care to those who have not responded to standard therapies, such as the analysis of multiple cohort studies, long-term studies following groups of people who have and do not have a given condition. Today, these tasks involve manually reviewing, parsing and consolidating the relevant information, typically in spreadsheets. These manual processes cause significant delays for patients waiting for care targeted at individual cancers.

With this project, SAP will aim to improve the accuracy of cancer diagnoses and, ultimately, patient outcomes by enabling integrated access to clinical information and analyzing complex data sets in real time. Built on the SAP HANA® platform, the project was developed in partnership with the German National Center for Tumor Diseases (NCT) and is now in use for testing purposes at its facilities in Heidelberg.

"We are now able to extract and analyze data from various sources and present it to physicians and researchers in a way that enables surprising new insights," said Professor Dr. Christof von Kalle, director, translational oncology, NCT. "In the future, we would like to use the SAP HANA platform for every diagnostic and therapeutic step, because every cancer is different and can vary immensely from one patient to the next."

"Medical Insights" is envisioned to use a generic healthcare data model and semantic capabilities to pull patient data from many different sources, such as clinical information systems, tumor registries, biobank systems and even text documents like a physician's notes. It will then run the advanced data analytics on the underlying SAP HANA platform and provide the results in real time. This is meant to help increase efficiency among various medical teams so that doctors have the most up-to-date information on their patients allowing for a faster, more accurate diagnosis. Patient cohorts are pictured to be posted and edited collaboratively, exported for further analysis in other software or compared according to different metrics.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs